Compare PPTA & STOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PPTA | STOK |
|---|---|---|
| Founded | 2011 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.0B |
| IPO Year | 2011 | 2019 |
| Metric | PPTA | STOK |
|---|---|---|
| Price | $15.42 | $26.81 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 14 |
| Target Price | $36.90 | ★ $46.38 |
| AVG Volume (30 Days) | ★ 1.7M | 938.4K |
| Earning Date | 11-13-2026 | 10-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 92.73 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $184,420,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $35.58 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 404.50 |
| 52 Week Low | $15.31 | $22.05 |
| 52 Week High | $37.37 | $40.22 |
| Indicator | PPTA | STOK |
|---|---|---|
| Relative Strength Index (RSI) | 35.94 | 50.80 |
| Support Level | N/A | $25.65 |
| Resistance Level | $19.12 | $33.39 |
| Average True Range (ATR) | 1.39 | 1.33 |
| MACD | -0.16 | 0.00 |
| Stochastic Oscillator | 7.34 | 35.55 |
Perpetua Resources Corp is engaged in acquiring mining properties with the intention of exploring, evaluating, developing and placing them into production, if warranted. Its principal mineral project is the Stibnite Gold Project in Idaho, USA, which contains several gold, silver and antimony mineral deposits. The company's current focus is to redevelop three of the Deposits known as the Hangar Flats Deposit, West End Deposit and Yellow Pine Deposit, all of which are located within the Stibnite Gold Project, as well as reprocess certain historical tailings located on the Project. It operates in one segment: mineral exploration and development in the United States.
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.